CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human...
Sujata Setia, Mithail Afrige Chowdhury and Steve Gschmeissner awarded £10,000 each for images exploring domestic abuse, climate migration and the...
Geopolitics is now a core operational risk for supply chains WASHINGTON, July 24, 2025 /PRNewswire/ -- With the August 1 deadline...
SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty...
Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases...
– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to...
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER...
Basel, 24 July 2025 Group sales grew by 7%1 at constant exchange rates (CER; 4% in CHF), driven by strong...
Spanning 11 studies across the U.S., Canada, Sweden, and Australia, the newly funded research explores interventions for young people dealing...
Proven drug development leader to drive company’s pipeline of highly CNS-penetrant and precision-designed peripherally restricted small molecules toward clinical milestonesSOUTH SAN...
Proven drug development leader to drive company’s pipeline of highly CNS-penetrant and precision-designed peripherally restricted small molecules toward clinical milestonesSOUTH SAN...
NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small...
Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences,...
– 25-year industry veteran Vanessa L. Jacoby appointed CBO and CFO, bringing financial and strategic leadership – – Enrollment initiated...
During the year ended April 30, 2025, net cash provided by financing activities was $10.4 millionStockholder equity of $4.0 million...
Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, July 23, 2025 (GLOBE NEWSWIRE)...
WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics...
MIDDLETON, Wis., July 22, 2025 /PRNewswire/ -- Natus Medical Incorporated is continuing its commitment to innovation and expanding the functionality of...
Powering Alzheimer's research with AI-driven insights across cognition, meaning, motor function, and speech — accelerating study recruitment and enabling more...
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products...